Press Releases

Tepha's cutting edge technology has been a hot topic of discussion in the medical device community since the company's inception. Please browse the database of news and press releases for the latest highlights of Tepha’s accomplishments. You may use and republish any of the press releases on this site for any legitimate media purpose as long as you reference Tepha, Inc. or the original source.
May 1, 2009. TEPHA PARTNER LAUNCHES NOVEL MONOFILAMENT ABSORBABLE SUTURE UTILIZING TEPHA’s PROPRIETARY BIOMATERIAL
Tepha Corporate Partner, Aesculap AG, Introduces MonoMax® Monofilament Suture at the German Surgical Congress in Munich following Receipt of CE Mark.
July 24, 2008. Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer
Tepha, Inc., a developer of medical devices derived from a new class of resorbable polymers, announced today that it has appointed John Hartnett to the new position of Executive Vice President and Chief Operating Officer.
April 17, 2008. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Tepha, Inc., a developer of medical devices derived from a new class of polymers, announced today that two of its corporate partners, Aesculap and Tornier, are conducting initial clinical evaluations of the Company's new TephaFLEX® suture products. These clinical evaluations, conducted in both the United States and Europe, represent the first human usage of medical devices derived from Tepha's new class of resorbable polymers called polyhydroxyalkanoates ("PHA's").
June 6, 2007. Tepha, Inc. Announces $10.7 Million Venture Capital Financing
Tepha, Inc., a privately held medical device company, today announced that it had closed a $10.7 million financing led by The Vertical Group. Also participating in the financing were Integra Ventures, Novartis Venture Fund, and Westfield Life Sciences Fund. The funds will be used to support the further development of Tepha's unique biopolymer technology platform including materials processing, device testing, and regulatory submissions.
Apr 2, 2007. Tepha, Inc. Receives FDA Clearance for First Medical Device Derived from New Class of Biopolymers
Tepha, Inc., a privately held medical device company, today announced that the FDA has cleared its TephaFLEX® Absorbable Suture product for marketing in the U.S. The TephaFLEX Absorbable Suture is the first medical device derived from a new class of biopolymers that is the product of patented recombinant DNA technology developed by Tepha and the Massachusetts Institute of Technology (MIT).
November 22, 2004. Tepha, Inc. Closes $4.3 Million Financing
Tepha, Inc., a privately held Boston-area medical device company, today announced that it has closed a $4.3 million financing led by The Vertical Group. Also participating in the financing were Integra Ventures, and Novartis Venture Fund. The funds will be used to complete the submissions of Premarket Notification 510(k) Applications to the FDA for the Company’s first products, as well as for research and development and working capital.
January 9, 2004. Tepha, Inc. Submits Device Master File for its elastomeric TephELAST™ biomaterial to the Food and Drug Administration.
Tepha, Inc., a privately-held Boston-area medical device company, announces the accomplishment of submission of a Device Master File (DMF) to the United States Food and Drug Administration (FDA) in December 2003 for its polyhydroxyalkanoate (PHA) copolymer, TephELAST™ biomaterial, a.k.a. PHA 3444.